U.S. market Open. Closes in 3 hours 41 minutes

PDSB | PDS Biotechnology Corporation Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.1100 - 2.2500
52 Week Range 1.5300 - 6.68
Beta 1.43
Implied Volatility 301.49%
IV Rank 75.64%
Day's Volume 478,066
Average Volume 403,888
Shares Outstanding 37,409,100
Market Cap 83,235,248
Sector Healthcare
Industry Biotechnology
IPO Date 2015-09-30
Valuation
Profitability
Growth
Health
P/E Ratio -1.90
Forward P/E Ratio -4.90
EPS -1.17
1YR Price Target 21.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 25
Country USA
Website PDSB
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
*Chart delayed
Analyzing fundamentals for PDSB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see PDSB Fundamentals page.

Watching at PDSB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PDSB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙